Get started
Author

Mata Charokopou

Observed names: M Charokopou, M. Charokopou
OpenAlex ID: A5113828454
Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis
2017 · Floortje van Nooten, Maarten Treur, et al. · Clinical Therapeutics · 121
Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older
2020 · Emma Söreskog, Oskar Ström, et al. · Bone · 82
PDF
Imminent fracture risk assessments in the UK FLS setting: implications and challenges
2019 · Rafael Pinedo-Villanueva, Mata Charokopou, et al. · Archives of Osteoporosis · 44
PDF
Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013
2015 · M. Charokopou, F.J. Sabater, et al. · Current Medical Research and Opinion · 44
The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments
2020 · Noem Sain, Damon Willems, et al. · Current Medical Research and Opinion · 42
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
2015 · M. Charokopou, P. McEwan, et al. · BMC Health Services Research · 41
PDF
Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland? A Retrospective Analysis 2006–2013
2015 · Mata Charokopou, Istvan M. Majer, et al. · Value in Health · 37
PDF
The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus
2015 · M. Charokopou, P. McEwan, et al. · Diabetic Medicine · 34
A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs
2017 · Edward Atkinson-Clark, Mata Charokopou, et al. · Epilepsy & Behavior · 20
PDF
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
2021 · H. Hagino, K. Tanaka, et al. · Osteoporosis International · 18
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
2016 · L. H. Chuang, B. G. Verheggen, et al. · Journal of Medical Economics · 17
PDF
Importance of Time Point–Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses
2022 · Damon Willems, Muhammad Kassim Javaid, et al. · Clinical Therapeutics · 15
A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
2021 · E. Söreskog, F. Borgström, et al. · Osteoporosis International · 14
PDF
Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
2019 · Saku Väätäinen, Erkki Soini, et al. · Advances in Therapy · 11
PDF
Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system
2019 · Mary Geitona, Eugena Stamuli, et al. · Journal of Medical Economics · 10
PDF
PNS22 Network Meta-Analysis: A Comparison of Bayesian and Frequentist Approaches to Synthesis, and Evaluation of Their Suitability for Decision-Making
2020 · R. Harvey, M. Charokopou, et al. · Value in Health · 9
PDF
Proposal for capturing patient experience through extended value frameworks of health technologies
2021 · András Inotai, Ivett Jakab, et al. · Journal of Managed Care & Specialty Pharmacy · 8
PDF
Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis
2019 · Mata Charokopou, Rebecca Harvey, et al. · Current Medical Research and Opinion · 8
Early health economic modelling for a treatment candidate in hidradenitis suppurativa
2020 · Damon Willems, Mata Charokopou, et al. · Journal of Medical Economics · 7
Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden
2024 · Chiara Malmberg, Magnus Värendh, et al. · Applied Health Economics and Health Policy · 3
Response to Zhang et al.: Levetiracetam vs. brivaracetam for adults with refractory focal seizures: A meta-analysis and indirect comparison
2016 · Simon Borghs, Mata Charokopou, et al. · Seizure · 3
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective
2014 · M. Charokopou, H. Vioix, et al. · Value in Health · 3
The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Glipizide in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
2013 · M. Charokopou, P. McEwan, et al. · Value in Health · 3
PDF
The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus a DPP-4 Inhibitor in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
2013 · M. Charokopou, P. McEwan, et al. · Value in Health · 3
Cost-Effectiveness of Brivaracetam Versus Other Antiepileptic Drugs Used as Adjunctive Treatment for Focal Seizures in the Uk: A Discrete Event Simulation Model
2016 · M Charokopou, J Sander, et al. · Value in Health · 2
Works count: 57
Citation count: 624
H-index: 13
I10-index: 15
Year
Topic
Type